. 2014 May 16;3(3):e000732. doi: 10.1161/JAHA.113.000732

Table 2.

Subgroup Analyses, Endpoint‐Specific Analyses, and Sensitivity Analyses

		Model 1			Model 2			Model 3
	HbA_1c Group	HR [95% CI]	P Value	P _interaction	HR [95% CI]	P Value	P _interaction	HR [95% CI]	P Value	P _interaction
Full sample	<6.5%	1.10 [0.75, 1.62]	0.629	0.082	1.11 [0.74, 1.66]	0.623	0.117	1.13 [0.75, 1.69]	0.563	0.149
Full sample	≥6.5%	0.47 [0.19, 1.13]	0.092	0.082	0.48 [0.18, 1.26]	0.136	0.117	0.52 [0.19, 1.39]	0.189	0.149
Subgroups
Age<75 y	<6.5%	0.98 [0.59, 1.63]	0.949	0.715	0.95 [0.57, 1.58]	0.834	0.767	0.98 [0.58, 1.64]	0.928	0.564
Age<75 y	≥6.5%	0.79 [0.26, 2.35]	0.666	0.715	0.77 [0.23, 2.65]	0.682	0.767	0.66 [0.19, 2.31]	0.511	0.564
Age≥75 y	<6.5%	1.22 [0.65, 2.27]	0.536	0.035	1.35 [0.68, 2.68]	0.390	0.081	1.30 [0.65, 2.60]	0.451	0.083
Age≥75 y	≥6.5%	0.11 [0.01, 0.95]	0.044	0.035	0.18 [0.02, 1.55]	0.118	0.081	0.17 [0.02, 1.53]	0.115	0.083
Men	<6.5%	0.98 [0.59, 1.62]	0.938	0.986	0.94 [0.55, 1.60]	0.810	0.821	0.93 [0.54, 1.60]	0.795	0.796
Men	≥6.5%	0.97 [0.24, 3.92]	0.963	0.986	0.78 [0.17, 3.64]	0.748	0.821	0.75 [0.16, 3.60]	0.719	0.796
Women	<6.5%	1.36 [0.72, 2.55]	0.339	0.018	1.46 [0.76, 2.79]	0.258	0.074	1.59 [0.82, 3.09]	0.171	0.110
Women	≥6.5%	0.27 [0.08, 0.88]	0.030	0.018	0.40 [0.11, 1.40]	0.151	0.074	0.47 [0.13, 1.77]	0.264	0.110
Individual endpoints
Stroke	<6.5%	0.87 [0.53, 1.45]	0.601	0.337	0.94 [0.56, 1.58]	0.823	0.645	0.96 [0.57, 1.62]	0.883	0.691
Stroke	≥6.5%	0.48 [0.16, 1.47]	0.198	0.337	0.67 [0.18, 2.56]	0.563	0.645	0.72 [0.19, 2.76]	0.630	0.691
Myocardial infarction	<6.5%	1.51 [0.84, 2.71]	0.165	0.201	1.43 [0.78, 2.63]	0.246	0.100	1.43 [0.78, 2.62]	0.254	0.081
Myocardial infarction	≥6.5%	0.59 [0.16, 2.20]	0.433	0.201	0.38 [0.09, 1.64]	0.197	0.100	0.35 [0.08, 1.52]	0.160	0.081
Sensitivity analyses
Age as time scale	<6.5%	1.09 [0.74, 1.61]	0.659	0.114	1.10 [0.74, 1.66]	0.630	0.146	1.13 [0.75, 1.70]	0.553	0.176
Age as time scale	≥6.5%	0.50 [0.21, 1.21]	0.125	0.114	0.51 [0.19, 1.34]	0.171	0.146	0.54 [0.20, 1.46]	0.226	0.176
No HbA_1c imputation	<6.5%	1.08 [0.72, 1.61]	0.708	0.255	1.10 [0.73, 1.67]	0.640	0.252	1.10 [0.73, 1.67]	0.649	0.346
No HbA_1c imputation	≥6.5%	0.60 [0.24, 1.52]	0.281	0.255	0.59 [0.21, 1.60]	0.297	0.252	0.64 [0.23, 1.82]	0.408	0.346
Subjects with prior CVD excluded	<6.5%	1.24 [0.80, 1.90]	0.332	0.130	1.23 [0.79, 1.92]	0.357	0.233	1.27 [0.82, 1.99]	0.287	0.233
Subjects with prior CVD excluded	≥6.5%	0.55 [0.21, 1.44]	0.222	0.130	0.63 [0.23, 1.73]	0.373	0.233	0.65 [0.23, 1.81]	0.409	0.233

HR [95% CI] and P value are for the comparison of Hp 2‐2 versus other genotypes among subjects with glycosylated hemoglobin (HbA_1c) <6.5% or HbA_1c≥6.5%, respectively. P_interaction is for a difference in the effect of dichotomized Hp genotype between those with HbA_1c<6.5% and those with HbA_1c≥6.5%. Model 1: adjustment for age and sex; Model 2: as model 1, with additional adjustment for current smoking, systolic blood pressure, LDL cholesterol, and HDL cholesterol; Model 3: as model 2, with additional adjustment for metabolic equivalent hours, alternative healthy eating index, statin use, and body mass index. CVD indicates cardiovascular disease; HbA_1c, glycosylated hemoglobin; HR, hazard ratio.